Literature DB >> 8893375

Autoantibodies and target antigens in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides.

J A Savige1, L Chang, D Wilson, R R Buchanan.   

Abstract

In this study of antineutrophil cytoplasmic antibody (ANCA)-associated diseases, we determined the prevalence of other autoantibodies and the antigen specificities of ANCA. ANA were common, occurring in 7 of 36 (19%) patients with Wegener's granulomatosis, in 16 of 34 (47%) patients with microscopic polyarteritis, in 6 of 11 (55%) patients with segmental necrotising glomerulonephritis and in 8 of 18 (44%) of those with ANCA-associated systemic vasculitis without renal involvement. ANA were associated more often with pANCA and microscopic polyarteritis than with cANCA (P < 0.05). Patterns were speckled (n = 23), homogeneous (n = 10) or nucleolar (n = 4). Anticardiolipin antibodies were also common, occurring in 10 of 25 (40%) patients with Wegener's granulomatosis, in 8 of 14 (57%) patients with microscopic polyarteritis and in 6 of 18 (33%) of those with a systemic vasculitis. However, anticardiolipin antibodies did not correlate with the presence of ANCA in any of the disease groups. Anti-GBM antibodies were demonstrated in only 2 of 25 (8%) patients with Wegener's granulomatosis, in 1 patient with microscopic polyarteritis (1/14, 7%) and in 1 with segmental necrotising glomerulonephritis (1/11, 9%). All four patients with anti-GBM antibodies had either cANCA or pANCA. In the second part of the study, the target antigens of ANCA were determined in Wegener's granulomatosis, microscopic polyarteritis, systemic vasculitis, inflammatory bowel disease, rheumatoid arthritis and systemic lupus erythematosus (SLE). Of the 19 sera with cANCA, 13 (68%) were directed against proteinase 3; other antigens were myeloperoxidase (1/19, 5%), elastase and lactoferrin together (1/19, 5%), lysozyme (1/19, 5%) or unknown (3/19, 16%). Of the 12 (58%) sera from patients with Wegener's granulomatosis who had cANCA, 7 bound to proteinase 3. Antimyeloperoxidase antibodies were present in 14 of 45 (31%) sera with pANCA; other antigens were proteinase 3 (5/45, 11%), elastase (3/45, 78%), lactoferrin (1/45, 2%), cathepsin G (5/45, 11%) or unknown (17/45, 38%). Antimyeloperoxidase antibodies were common in microscopic polyarteritis (6/14, 43%) and systemic vasculitis (5/16, 31%). However, the majority of target antigens in systemic vasculitis and rheumatoid arthritis with pANCA were not determined. "Atypical" ANCA were present in four patients, one with inflammatory bowel disease (1/8, 13%) and three with SLE (3/15, 20%). The specificities were cathepsin G, cathepsin G plus lactoferrin, or unknown in two sera. A recent report has suggested that bactericidal/permeability-increasing protein may be the target in patients with inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8893375     DOI: 10.1007/bf01409982

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  32 in total

1.  Evolution of membranous nephropathy into anti-glomerular-basement-membrane glomerulonephritis.

Authors:  J Klassen; C Elwood; A L Grossberg; F Milgrom; M Montes; M Sepulveda; G A Andres
Journal:  N Engl J Med       Date:  1974-06-13       Impact factor: 91.245

Review 2.  Granulocyte-specific antinuclear antibodies. Possible significance for the pathogenesis, clinical features and diagnosis of rheumatoid arthritis.

Authors:  A Wiik
Journal:  Allergy       Date:  1980-06       Impact factor: 13.146

3.  Incidence and specificity of p-ANCA in rheumatic diseases.

Authors:  M G Braun; E Csernok; W H Schmitt; W L Gross
Journal:  Adv Exp Med Biol       Date:  1993       Impact factor: 2.622

4.  Autoantibodies to endothelial cells and neutrophil cytoplasmic antigens in systemic vasculitis.

Authors:  G Frampton; D R Jayne; G J Perry; C M Lockwood; J S Cameron
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

5.  Autoantibodies against neutrophil cytoplasm components in systemic lupus erythematosus and in hydralazine-induced lupus.

Authors:  L Nässberger; A G Sjöholm; H Jonsson; G Sturfelt; A Akesson
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

6.  ANCA with specificity for lactoferrin in systemic lupus erythematosus (SLE).

Authors:  R A Sinico; C Pozzi; A Radice; A Tincani
Journal:  Adv Exp Med Biol       Date:  1993       Impact factor: 2.622

7.  Anti-myeloperoxidase antibodies: immunological characteristics and clinical associations.

Authors:  P Gueirard; A Delpech; D Gilbert; M Godin; X Le Loet; F Tron
Journal:  J Autoimmun       Date:  1991-06       Impact factor: 7.094

8.  Antilactoferrin antibodies in patients with rheumatoid arthritis are associated with vasculitis.

Authors:  I E Coremans; E C Hagen; M R Daha; F J van der Woude; E A van der Voort; C Kleijburg-van der Keur; F C Breedveld
Journal:  Arthritis Rheum       Date:  1992-12

9.  Anti-neutrophil cytoplasmic antibodies (ANCA) directed against bactericidal/permeability increasing protein (BPI): a new seromarker for inflammatory bowel disease and associated disorders.

Authors:  M P Stoffel; E Csernok; C Herzberg; T Johnson; S F Carroll; W L Gross
Journal:  Clin Exp Immunol       Date:  1996-04       Impact factor: 4.330

10.  Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils.

Authors:  R Goldschmeding; C E van der Schoot; D ten Bokkel Huinink; C E Hack; M E van den Ende; C G Kallenberg; A E von dem Borne
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

View more
  7 in total

1.  pANCA antibodies in patients with anterior uveitis: identification of a marker antibody usually associated with ulcerative colitis.

Authors:  L K Gordon; M Eggena; G N Holland; J M Weisz; J Braun
Journal:  J Clin Immunol       Date:  1998-07       Impact factor: 8.317

2.  Long-Term Prognostic Factors in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A 15-Year Multicenter Retrospective Study.

Authors:  Qian-Qian Liao; Ya-Fei Ren; Ke-Wei Zhu; Dong Qin; Yan-Ju Mo; Shan Cong; Juan Wu; Chun-Ying Wang; Xiao-Jiao Cui; Hong-Zhen Xu; Lin-Zheng Guo; You-Yan Zhang; Hai-Xia Song; Wei Zhang; Zhe Yang; Yan-Feng Tang; Zhuo-Jun Li; Zhou-Ni Xie; Li-Mei Li; Hui-Juan Wang; Meng-Meng Zhou; Fang-Ning Wei; Peng Chen; Yu-Hong Shi
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

3.  Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis.

Authors:  Despina Michailidou; Bhargavi Duvvuri; Runa Kuley; David Cuthbertson; Peter C Grayson; Nader A Khalidi; Curry L Koening; Carol A Langford; Carol A McAlear; Larry W Moreland; Christian Pagnoux; Philip Seo; Ulrich Specks; Antoine G Sreih; Kenneth J Warrington; Tomas Mustelin; Paul A Monach; Peter A Merkel; Christian Lood
Journal:  Arthritis Res Ther       Date:  2022-06-29       Impact factor: 5.606

4.  Antibodies to selected minor target antigens in patients with anti-neutrophil cytoplasmic antibodies (ANCA).

Authors:  M V Talor; J H Stone; J Stebbing; J Barin; N R Rose; C L Burek
Journal:  Clin Exp Immunol       Date:  2007-07-05       Impact factor: 4.330

5.  A Cross-Sectional Study of the Association between Autoantibodies and Qualitative Ultrasound Index of Bone in an Elderly Sample without Clinical Autoimmune Disease.

Authors:  Rosebella A Iseme; Mark McEvoy; Brian Kelly; Linda Agnew; Frederick R Walker; Michael Boyle; John Attia
Journal:  J Immunol Res       Date:  2018-04-30       Impact factor: 4.818

Review 6.  Role of Neutrophils in Systemic Vasculitides.

Authors:  Despina Michailidou; Tomas Mustelin; Christian Lood
Journal:  Front Immunol       Date:  2020-12-17       Impact factor: 7.561

7.  Clinical and pathological characteristics of ANA/anti-dsDNA positive patients with antineutrophil cytoplasmic autoantibody-associated vasculitis.

Authors:  Xiaohong Zhao; Qiong Wen; Yagui Qiu; Fengxian Huang
Journal:  Rheumatol Int       Date:  2020-09-22       Impact factor: 2.631

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.